Table 5.
Day | 27 | 28 | 29 | 30 | 31 | Prevalence per Trial Group (%) |
---|---|---|---|---|---|---|
Trial Group | ||||||
Control | 13 | nd | 7 | 8340 | nd | 60 a |
LS | 20 | nd | nd | nd | 40 | 40 b |
LA | nd | nd | nd | nd | nd | 0 b |
Formulation C | 13 | nd | nd | nd | 80 | 40 b |
Formulation L | 7 | nd | nd | 539 | nd | 40 b |
LS + C | nd | nd | 20 | nd | nd | 20 b |
LS + L | nd | nd | nd | nd | nd | 0 b |
LA + C | nd | 63 | nd | 25 | nd | 40 b |
LA + L | nd | nd | nd | 7 | nd | 20 b |
Prevalence (%): positive samples per day | 44 | 11 | 22 | 44 | 22 | |
p 1 | 0.001 |
nd: not detected. 1 Significant differences were determined using the chi-squared test, different letters indicate significant differences (p < 0.05) in the overall prevalence of ESBL-producing Enterobacteriaceae between trial groups.